

CITATION REPORT

List of articles citing

Enhancing incretin action for the treatment of type 2 diabetes

DOI: 10.2337/diacare.26.10.2929
Diabetes Care, 2003, 26, 2929-40.

Source: <https://exaly.com/paper-pdf/35760786/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
480	Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. 2003 , 144, 5145-8		233
479	Overview of incretin hormones. 2004 , 36, 742-6		53
478	GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. 2004 , 36, 867-76		187
477	Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. 2004 , 145, 2653-9		448
476	Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. <i>Diabetes Care</i> , 2004 , 27, 1077-80	14.6	60
475	A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. 2004 , 53, 2492-500		290
474	Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. 2004 , 53 Suppl 3, S205-14		63
473	Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice. 2004 , 498, 319-23		10
472	An aminomethylpyrimidine DPP-IV inhibitor with improved properties. 2004 , 14, 3575-8		37
471	Aminomethylpyridines as DPP-IV inhibitors. 2004 , 14, 3579-80		21
470	Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. 2004 , 127, 546-58		294
469	Mechanisms and therapeutic targets in type 2 diabetes mellitus. 2004 , 1, 151-157		26
468	Beta- and alpha-cell dysfunction in type 2 diabetes. 2004 , 36, 775-81		88
467	Glucose Metabolism and Regulation: Beyond Insulin and Glucagon. 2004 , 17, 183-190		281
466	Overview of diabetes. 2004 , 27, 106-12		15
465	Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. 2004 , 286, E882-90		61
464	Importance of gut hormones in gastrointestinal, metabolic, and malignant diseases. 2005 , 12, 80-88		2

463	Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. 2005 , 143, 559-69		628
462	Unique characteristics of the geriatric diabetic population and the role for therapeutic strategies that enhance glucagon-like peptide-1 activity. 2005 , 8, 9-16		11
461	Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. 2005 , 78, 675-88		375
460	Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 5025-37	8.3	511
459	Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. 2005 , 10, 417-27		306
458	Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. 2005 , 21, 313-31		56
457	Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. 2005 , 48, 2236-40		294
456	Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. 2005 , 5, 346-52		6
455	New mechanisms of action provide alternative therapies. 2005 , 20, 404-10, 413-4		
454	Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. 2005 , 14, 57-64		44
453	Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. 2005 , 54, 2436-46		140
452	Inhibitors of dipeptidyl peptidase IV--recent advances and structural views. 2005 , 5, 1623-37		32
451	Exenatide: A Novel Therapeutic Approach for Type 2 Diabetes Mellitus. 2005 , 21, 191-196		
450	Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. <i>Diabetes Care</i> , 2005 , 28, 1083-91	14.6	1034
449	Incretin mimetics as emerging treatments for type 2 diabetes. <i>Annals of Pharmacotherapy</i> , 2005 , 39, 110-8	2.9	59
448	Pdx-1 is not sufficient for repression of proglucagon gene transcription in islet or enteroendocrine cells. 2005 , 146, 441-9		12
447	beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. 2005 , 54, 482-91		183
446	Insulin, glucagon, and oral hypoglycemic drugs. 2005 , 509-527		1

445	Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). 2005 , 386, 679-87	29
444	Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes?. 2005 , 1, 70-1	
443	Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. 2005 , 1, 358-68	80
442	Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. 2005 , 54, 2988-94	440
441	Incretins, diabetes, and bariatric surgery: a review. 2005 , 1, 589-97; discussion 597-8	44
440	A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. 2005 , 64, 848-53	125
439	Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?. 2005 , 128, 159-65	137
438	Novel pharmacologic agents for type 2 diabetes. 2005 , 34, 155-97	37
437	Beyond Insulin Therapy. 2006 , 395-416	1
436	Gastrointestinal Peptide Hormones Regulating Energy and Glucose Homeostasis. 2006 , 161-181	1
435	Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. 2006 , 22, 1939-47	82
434	Glycemic control in the metabolic syndrome and implications in preventing cardiovascular disease. 2006 , 4, 315-27	3
433	Pharmacotherapies for diabetes management: an update for the practicing clinician. 2006 , 18, 379-89	3
432	Pharmacologic interventions for type 1 and type 2 diabetes. 2006 , 41, 589-604, vii	
431	Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. 2006 , 130, 44-54	197
430	Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. 2006 , 15, 431-42	67
429	Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. <i>Journal of Biological Chemistry</i> , 2006 , 281, 1159-68	5-4 167
428	Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. 2006 , 28, 55-72	237

427	Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. 2006 , 28, 652-65	70
426	Growth factors and beta cell replication. 2006 , 38, 931-50	113
425	Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. 2006 , 38, 860-72	42
424	Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide. 2006 , 15, 887-95	21
423	cGMP may have trophic effects on beta cell function comparable to those of cAMP, implying a role for high-dose biotin in prevention/treatment of diabetes. 2006 , 66, 323-8	18
422	Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. 2006 , 46, 876-86	117
421	What are incretins, and how will they influence the management of type 2 diabetes?. 2006 , 12, S2-12; quiz S14-6	4
420	. 2006 ,	4
419	Hyperinsulinemic hypoglycemia following gastric bypass surgery for obesity. 2006 , 13, 419-424	16
418	Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. 2006 , 23, 240-5	39
417	Unusual cause of emesis in an octogenarian: organoaxial gastric volvulus associated with paraesophageal diaphragmatic hernia. 2006 , 54, 555-7	5
416	DPP-4 inhibitors and their potential role in the management of type 2 diabetes. 2006 , 60, 1454-70	253
415	Dietary synergies in appetite control: distal gastrointestinal tract. 2006 , 14 Suppl 4, 171S-178S	11
414	Effect of glucagon-like peptide-1 on the beta cell response to glucose-dependent insulinotropic polypeptide in elderly patients with diabetes mellitus. 2006 , 54, 554-5	2
413	Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. 2006 , 49, 452-8	221
412	Differential effects of monounsaturated, polyunsaturated and saturated fat ingestion on glucose-stimulated insulin secretion, sensitivity and clearance in overweight and obese, non-diabetic humans. 2006 , 49, 1371-9	112
411	Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY. 2006 , 49, 1915-23	62
410	What to inject when oral agents fail?. 2006 , 6, 341-3	

409	Is glycemic variability important to assessing antidiabetes therapies?. 2006 , 6, 350-6	10
408	Is the metabolic syndrome a real clinical entity and should it receive drug treatment?. 2006 , 6, 357-64	6
407	How do different GLP-1 mimetics differ in their actions?. 2006 , 6, 365-72	4
406	GLP-1 based therapy for type 2 diabetes. 2006 , 28, 96-108	80
405	Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. 2006 , 26, 360-74	27
404	New and emerging strategies for reducing cardiometabolic risk factors. 2006 , 26, 13S-31S; quiz 43S-45S	9
403	Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. 2006 , 38, 838-44	62
402	Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. 2006 , 7, 1055-64	48
401	The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. 2006 , 290, E1118-23	78
400	Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. 2006 , 30, 1332-40	107
399	Glucagon and glucagon-like peptide receptors as drug targets. 2006 , 12, 1731-50	72
398	Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. <i>Diabetes Care</i> , 2006 , 29, 435-49	14.6 87
397	Review: Inhibition of dipeptidyl peptidase-4 with vildagliptin: a potential new treatment for type 2 diabetes. 2006 , 6, 150-156	12
396	Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. 2006 , 55, 1747-54	68
395	Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. 2006 , 318, 914-21	45
394	Incretin-based therapies: a clinical need filled by unique metabolic effects. 2006 , 32 Suppl 2, 65S-71S	11
393	Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. 2006 , 55, 1369-79	47
392	Peptidomics Technologies and Applications in Drug Research. 2006 , 113-135	2

391	Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. 2006 , 1, 329-341	18
390	Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide. 2006 , 190, 889-96	20
389	Exendin-4 potently decreases ghrelin levels in fasting rats. 2007 , 56, 143-51	79
388	Novel Approaches to Diabetes Treatment. 2007 , 140, 28-29	
387	Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes. 2007 , 20, 159-165	44
386	The physiology of incretin hormones and the basis for DPP-4 inhibitors. 2007 , 33, 55-6, 60-2, 65-6	18
385	Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. <i>Annals of Pharmacotherapy</i> , 2007 , 41, 51-60	2.9 35
384	Type 1 Diabetes in Adults. 2007 ,	0
383	11 Years of cyanopyrrolidines as DPP-IV inhibitors. 2007 , 7, 579-95	55
382	Adapting the GLP-1-signaling system to the treatment of type 2 diabetes. 2007 , 3, 15-23	6
381	GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus. 2007 , 1, 193-201	
380	beta-cell failure in diabetes and preservation by clinical treatment. 2007 , 28, 187-218	556
379	Preserved GLP-1 effects in a diabetic patient with Cushing's disease. 2007 , 115, 146-50	15
378	Safety and adverse effects associated with GLP-1 analogues. 2007 , 6, 417-22	6
377	Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. 2007 , 148, 4965-73	256
376	Allosteric modulators of class B G-protein-coupled receptors. 2007 , 5, 168-79	36
375	The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. 2007 , 146, 477-85	343
374	Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. 2007 , 14, 98-107	56

- 373 Insulin treatment in managing type 2 diabetes: challenges and opportunities. **2007**, Suppl Initiating Insulin, 9-21
- 372 Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. **2007**, 47, 159-64 39
- 371 Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. **2007**, 29, 1692-705 25
- 370 Discontinued drugs in 2006: renal, endocrine and metabolic drugs. **2007**, 16, 1517-23 3
- 369 Impact of weight-loss medications on the cardiovascular system: focus on current and future anti-obesity drugs. **2007**, 7, 273-88 17
- 368 67 th annual meeting of the American Diabetes Association. **2007**, 16, 1735-9
- 367 Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. **2007**, 23, 905-17 49
- 366 Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. **2007**, 23, 933-44 43
- 365 Le GLP-1 : de la physiologie à l'application thérapeutique. **2007**, 42, 199-206
- 364 L'Exatide Quoi ? Comment ? Pour qui ?. **2007**, 1, 75-79
- 363 Oral antidiabetic agents in type 2 diabetes. **2007**, 23, 945-52 68
- 362 Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. **2007**, 23, 919-31 137
- 361 The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. **2007**, 13, S2-16; quiz S17 8
- 360 Mecanismos cirúrgicos de controle do diabetes mellitus tipo 2 após cirurgia bariátrica. **2007**, 34, 343-346 4
- 359 Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. **2007**, 9, 186-93 122
- 358 Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. **2008**, 10, 18-33 16
- 357 Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. **2007**, 9 Suppl 1, 23-31 54
- 356 Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. **2007**, 61, 29-37 27

355	Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. 2007 , 61, 3-11		13
354	Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes. 2007 , 61, 38-48		10
353	Potential role of oral DPP-4 inhibitors in the ADA/EASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: recommendations for oral antidiabetic agents. 2007 , 61, 12-8		1
352	Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. 2007 , 61, 19-28		28
351	Type 2 diabetes mellitus: focus on new treatments and special populations. 2007 , 61, 1-2		1
350	A New Dawn for the Treatment of Type 2 Diabetes: Integrating Incretin Mimetics Into Clinical Practice. 2007 , 19, 1-24		1
349	A New Dawn for the Treatment of Type 2 Diabetes: Integrating Incretin Mimetics Into Clinical Practice. 2007 , 19, 1-24		
348	Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. 2007 , 27, 1163-80		39
347	New therapies for diabetes. 2007 , 8, 58-63; discussion 64-5		6
346	Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. <i>Diabetes Care</i> , 2007 , 30, 1487-93	14.6	382
345	A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. 2007 , 50, 259-67		380
344	Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. 2007 , 50, 1532-40		88
343	Gastroesophageal reflux disease in diabetic patients: a systematic review. 2007 , 39, 340-354		5
342	Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. 2008 , 10, 55-60		32
341	Combination pharmacotherapy with incretins: what works best and when?. 2008 , 8, 361-7		
340	DPP4 inhibitors: a new approach in diabetes treatment. 2008 , 25, 627-43		58
339	Les incrétines. 2008 , 22, 59-65		
338	The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. 2008 , 62, 8-14		49

337	Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. 2008 , 10, 376-86		204
336	The physiology and pharmacology of incretins in type 2 diabetes mellitus. 2008 , 10, 14-21		15
335	Gastrointestinal peptides controlling body weight homeostasis. 2008 , 155, 481-95		17
334	C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. 2008 , 75, 2325-33		31
333	ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity. 2008 , 590, 444-9		6
332	Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. 2008 , 48, 1171-8		113
331	Novedades en terapia hipoglucemiante. Fármacos con acción incretina. 2008 , 55, 73-77		
330	Adult diffuse nesidioblastosis: genetically or environmentally induced?. 2008 , 39, 3-8		67
329	Exendin-4 and exercise promotes beta-cell function and mass through IRS2 induction in islets of diabetic rats. <i>Life Sciences</i> , 2008 , 82, 503-11	6.8	32
328	Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. 2008 , 30, 1448-60		294
327	Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. <i>Diabetes Research and Clinical Practice</i> , 2008 , 79, 79-85	7.4	44
326	Glucagon-like peptide-1 in type 2 diabetes: the cell and beyond. 2008 , 10, 2-13		11
325	Incrélines et diabète, une petite révolution conceptuelle et thérapeutique (1). 2008 , 2008, 28-29		
324	Diabetes management in the hospital. 2008 , 92, 407-25, ix-x		12
323	Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. 2008 , 9, 1705-20		17
322	New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin. 2008 , 9, 1495-507		4
321	Racial disparity in glucagon-like peptide 1 and inflammation markers among severely obese adolescents. <i>Diabetes Care</i> , 2008 , 31, 770-5	14.6	37
320	The modulating effects of GLP-1 in type 2 diabetes. 2008 , 8, S1-S2		

319	Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. 2008 , 93, 459-64	102
318	Pharmacology of GLP-1-based therapies. 2008 , 8, S10-S18	5
317	The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. 2008 , 149, 5670-8	85
316	Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide. 2008 , 24, 3009-22	9
315	Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. 2008 , 48, 1389-99	50
314	Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. 2008 , 48, 592-8	166
313	Sitagliptin and Vildagliptin: Efficacy of Therapy in Type 2 Diabetes. 2008 , 2, 162-171	1
312	New combination treatments in the management of diabetes: focus on sitagliptin-metformin. <i>Vascular Health and Risk Management</i> , 2008 , 4, 743-51	4.4 33
311	Hypoglycemia associated with off-label sitagliptin use. 2008 , 1, 3-5	
310	Exenatide use in the management of metabolic syndrome: a retrospective database study. 2008 , 14, 993-9	20
309	DPP-4 Inhibitors and the Relations between Rosiglitazone and the Risk of Myocardial Infarction. 2008 , 51, 371	2
308	Can newer therapies delay the progression of type 2 diabetes mellitus?. 2008 , 14, 625-38	21
307	Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes. 2009 , 1, 1103-1119	1
306	Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction. 2009 , 18, 1247-59	45
305	Huang-Lian-Jie-Du-Tang supplemented with Schisandra chinensis Baill. and Polygonatum odoratum Druce improved glucose tolerance by potentiating insulinotropic actions in islets in 90% pancreatectomized diabetic rats. 2009 , 73, 2384-92	17
304	The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. <i>Diabetes Care</i> , 2009 , 32, 1649-55	14.6 359
303	Defining the importance of daily glycemic control and implications for type 2 diabetes management. 2009 , 121, 82-93	11
302	Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. 2009 , 160, 909-17	106

301	Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog. 2009 , 58, 243-9	28
300	Beyond glycemic control: treating the entire type 2 diabetes disorder. 2009 , 121, 68-81	19
299	Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. <i>Annals of Pharmacotherapy</i> , 2009 , 43, 1433-44	2.9 51
298	Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. 2009 , 40, 536-44	69
297	Recent and emerging anti-diabetes targets. 2009 , 29, 125-95	70
296	Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34. 2009 , 23, 1724-32	90
295	Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. 2009 , 13, 1762-72	101
294	GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism. 2009 , 19, 313-20	51
293	Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?. 2009 , 19, 217-229	103
292	Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. 2009 , 68, 883-90	31
291	Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. 2009 , 63, 46-55	171
290	Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. 2009 , 11, 786-94	151
289	Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. 2009 , 17, 1783-802	158
288	Emerging concepts in the pathophysiology of type 2 diabetes mellitus. 2009 , 76, 216-26	26
287	Unraveling the science of incretin biology. 2009 , 20 Suppl 2, S303-8	40
286	Unraveling the science of incretin biology. 2009 , 122, S3-S10	111
285	Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. 2009 , 10, 503-12	50
284	Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. 2009 , 24, 1061-6	86

283	Exendin-4 exerts its effects through the NGF/p75NTR system in diabetic mouse pancreas. 2009 , 87, 641-51	19
282	Dipeptidyl peptidase IV(DPP IV): a novel emerging target for the treatment of type 2 diabetes. 2009 , 23, 228-235	9
281	Incrétines et diabète, une petite révolution conceptuelle et thérapeutique (3) L'effet incrétine, un nouveau concept thérapeutique. 2009 , 2009, 26-27	
280	Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. 2009 , 111, 361-71	42
279	Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. 2009 , 56, 415-24	48
278	Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. 2009 , 56, 951-62	41
277	Dietary Fiber and Associated Phytochemicals in Prevention and Reversal of Diabetes. 2009 , 97-125	3
276	Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review. 2004 , 56, 1477-92	26
275	The effect of duodenal-jejunal bypass on glucose-dependent insulinotropic polypeptide secretion in Wistar rats. 2010 , 20, 768-75	8
274	Exendin-4 and exercise improve hepatic glucose homeostasis by promoting insulin signaling in diabetic rats. <i>Metabolism: Clinical and Experimental</i> , 2010 , 59, 123-33	12.7 12
273	Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. 2010 , 164, 58-64	125
272	Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. 2010 , 30, 463-84	103
271	Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. 2010 , 45, 202-7	116
270	Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. 2010 , 32, 1188-204	43
269	Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. 2010 , 64, 1619-31	137
268	Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome. 2010 , 72, 423-5	3
267	Gut hormones and the brain. 2010 , 2, 138-45	1
266	Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. 2010 , 12, 267-87	63

265	Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. 2010 , 12, 474-84		21
264	Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. 2010 , 27, 1024-32		125
263	Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. 2010 , 27, 1409-19		100
262	Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives. 2010 , 4, 61-8		13
261	Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. 2010 , 2, 7-19		12
260	Managing diabetes with new pharmaceutical agents. 2010 , 21, 634-638		
259	Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2010 , 6, 145-55	4-4	59
258	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , Volume 3, 215-226	3-4	20
257	Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , Volume 3, 363-372	3-4	4
256	Current developments in the treatment of diabetes: the incretin therapies. 2010 , 10, 21-30		1
255	Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus. 2010 , 67, 1326-36		9
254	Surgical interventions to correct metabolic disorders. 2010 , 10, 143-147		1
253	Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial). 2010 , 11, 2269-71		8
252	Diabetes Treatment: Insulin and Incretins. 2010 , 28, 177-182		1
251	Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. 2010 , 67, 1515-25		23
250	Review of liraglutide versus sitagliptin for patients with uncontrolled type 2 diabetes: more effective HbA 1c reduction with subcutaneous GLP-1 receptor agonist versus an oral DPP-4 inhibitor. 2010 , 122, 185-8		3
249	Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. 2010 , 95, 4206-16		86
248	Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 6412-20	8-3	70

247	Clinical approaches to preserve beta-cell function in diabetes. <i>Advances in Experimental Medicine and Biology</i> , 2010 , 654, 515-35	3.6	28
246	DPP-4 inhibitors: what may be the clinical differentiators?. <i>Diabetes Research and Clinical Practice</i> , 2010 , 90, 131-40	7.4	77
245	Effect of intracerebroventricular infusion of neurotensin in glucose-dependent insulinotropic peptide secretion in dogs. 2010 , 31, 150-4		7
244	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. 2010 , 20, 224-35		143
243	Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. 2010 , 123, S2-S10		26
242	Combination treatment of db/db mice with exendin-4 and gastrin preserves β cell mass by stimulating β cell growth and differentiation. <i>Journal of Diabetes Investigation</i> , 2010 , 1, 172-83	3.9	16
241	Add-on therapies to metformin for type 2 diabetes. 2011 , 12, 47-62		14
240	Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes. 2011 , 327-358		2
239	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. 2011 ,		6
238	Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. 2011 , 124, S3-18		220
237	Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. <i>Diabetes Research and Clinical Practice</i> , 2011 , 94, 217-24	7.4	79
236	GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1. 2011 , 32, 1303-12		30
235	Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. <i>Journal of Diabetes Investigation</i> , 2011 , 2, 210-7	3.9	43
234	Incretines. 2011 , 50, 49-52		
233	Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus. 2011 ,		
232	. 2011 ,		1
231	Gastroplastia como tratamento do diabetes melito tipo 2. 2011 , 24, 285-289		2
230	Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts. 2011 , 30, 34-44		13

229	Weight considerations in pharmacotherapy for type 2 diabetes. 2011 , 2011,	21
228	Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity. 2011 , 35, 149-58	30
227	Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. 2011 , 13, 207-20	55
226	Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. 2011 , 13, 639-43	18
225	Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. 2011 , 13, 703-10	73
224	The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and suprathreshold doses. 2011 , 72, 39-50	27
223	Isoflavonoids and peptides from meju, long-term fermented soybeans, increase insulin sensitivity and exert insulinotropic effects in vitro. 2011 , 27, 244-52	88
222	Short-term and mid-term control of type 2 diabetes mellitus by laparoscopic sleeve gastrectomy with ileal interposition. 2011 , 35, 2238-44	31
221	Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125. 2011 , 19, 172-85	21
220	Synthesis and pharmacological characterization of potent, selective, and orally bioavailable isoindoline class dipeptidyl peptidase IV inhibitors. 2011 , 1, 7	13
219	Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors. 2011 , 21, 1880-6	15
218	Binding specificity of the ectodomain of the parathyroid hormone receptor. 2011 , 154, 66-72	8
217	Sitagliptin and metformin--novel combination therapy. 2011 , 12, 641-6	3
216	Liraglutide for type 2 diabetes mellitus. 2011 , 11, 951-9	3
215	Dual-monoclonal, sandwich immunoassay specific for glucose-dependent insulinotropic peptide1-42, the active form of the incretin hormone. 2011 , 57, 849-55	10
214	Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. 2011 , 60, 1561-5	235
213	Need for better diabetes treatment for improved renal outcome. 2011 , S28-32	41
212	Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. 2011 , 123, 53-65	14

211	Ileal interposition with sleeve gastrectomy for treatment of type 2 diabetes mellitus. 2012 , 16, 589-98		22
210	What have we learned about the treatment of type 2 diabetes? The evolving paradigms. 2012 , 19, 449-64		2
209	Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. 2012 , 28, 1635-45		25
208	Cardioprotective effects of incretin during ischaemia-reperfusion. 2012 , 9, 256-69		25
207	Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. 2012 , 62, 75-82		2
206	The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety. 2012 , 124, 54-61		11
205	Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus. <i>Annals of Pharmacotherapy</i> , 2012 , 46, 812-21	2.9	13
204	Anti-inflammatory properties of exenatide in human pancreatic islets. 2012 , 21, 633-48		44
203	Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucagon-like peptide-1 analogues. 2012 , 19, 203-11		5
202	Evolving treatment strategies for the management of type 2 diabetes. 2012 , 343, 21-6		13
201	Antidiabetic Compounds from Marine Organisms and Their Properties. 2012 , 7-20		
200	Discontinued drugs 2011: endocrine and metabolic. 2012 , 21, 1619-24		2
199	Receptor-mediated inhibition of small bowel migrating complex by GLP-1 analog ROSE-010 delivered via pulmonary and systemic routes in the conscious rat. 2012 , 179, 71-6		7
198	Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus. 2012 , 11, 144-9		37
197	Formation of cyclic structure at amino-terminus of glucagon-like peptide-1 exhibited a prolonged half-life in vivo. <i>Diabetes Research and Clinical Practice</i> , 2012 , 96, 362-70	7.4	1
196	Management of Type 2 Diabetes Mellitus. 2012 , 167-191		
195	Newer Diabetes Medications. 2012 , 375-417		
194	Vesiculopustular dermatosis: an uncommon side-effect of liraglutide?. 2012 , 26, 458-9		7

193	Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes. 2012 , 38, 298-308		11
192	Laparoscopic ileal interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes. 2012 , 6, 125-31		25
191	Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. 2012 , 33, 1379-86		13
190	An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists. 2012 , 14, 951-67		23
189	Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus. 2012 , 10, 152		17
188	Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. <i>PLoS ONE</i> , 2012 , 7, e35007	3.7	42
187	Managing the Broad Spectrum of Type 2 Diabetes. 2012 , 43-56		
186	The Evolution of Glucose-Lowering Drugs for Type 2 Diabetes. 2012 , 459-474		1
185	Glucagon-like peptide-1 agonists. 2012 , 344, d7282		2
184	Liraglutide in Combination with Metformin or Sulfonylurea for the Treatment of Type 2 Diabetes in Adult patients. 2012 , 4, CMT.S7283		
183	Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. 2012 , 11, 6		61
182	The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. 2012 , 14, 5-14		342
181	Viscous versus nonviscous soluble fiber supplements: mechanisms and evidence for fiber-specific health benefits. 2012 , 24, 476-87		73
180	Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model. 2012 , 162, 9-18		20
179	Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. 2012 , 14, 365-71		23
178	Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures. <i>Diabetes Therapy</i> , 2013 , 4, 269-83	3.6	7
177	New leads for DPP IV inhibition: structure-based pharmacophore mapping and virtual screening study. 2013 , 36, 1326-37		8
176	Saxagliptin overview: special focus on safety and adverse effects. 2013 , 12, 103-9		27

175	Choice of early treatment regimen and impact on β cell preservation in type 2 diabetes. 2013 , 67, 876-87	15
174	Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data. 2013 , 8, 105-121	8
173	Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies. 2013 , 5, 43-50	
172	Review article: a comparison of glucagon-like peptides 1 and 2. 2013 , 37, 18-36	75
171	Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013. 2013 , 5, 241-53	8
170	Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus. 2013 , 70, 1123-31	10
169	The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. <i>Behavioural Brain Research</i> , 2013 , 237, 164-71	3-4 60
168	An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. 2013 , 2013, 591056	13
167	[Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin]. 2013 , 141, 339-49	5
166	Liraglutide prevents diabetes progression in prediabetic OLETF rats. 2013 , 60, 15-28	23
165	Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged \geq 65 years) with inadequately controlled type 2 diabetes mellitus. 2013 , 8, 419-30	32
164	Dipeptidyl Peptidase-IV Inhibitory Activity of Peptides in Porcine Skin Gelatin Hydrolysates. 2013 ,	10
163	Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide. 2014 , 2014, 304032	14
162	Clinical and laboratory characteristics of exenatide-given patients in endocrinology clinic of a university hospital. 2014 , 41, 128-132	1
161	A short-acting GLP-1 analog or prandial insulin to supplement basal insulin?--Moving toward personalized management of type 2 diabetes mellitus. 2014 , 126, 135-44	10
160	Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. 2014 , 16, 451-6	11
159	Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. 2014 , 16, 206-14	7
158	Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study. 2014 , 36, 101-14	5

157	Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabetes. 2014 , 31, 45-57		1
156	Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion. <i>Life Sciences</i> , 2014 , 94, 115-21	6.8	29
155	Long-acting GLP-1 analogue in V-shaped conformation by terminal polylysine modifications. 2014 , 11, 4092-9		17
154	Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. 2014 , 63, 3891-905		64
153	Cardiovascular effects of incretin therapy in diabetes care. 2014 , 12, 303-10		8
152	The G protein-coupled receptor P2Y14 influences insulin release and smooth muscle function in mice. <i>Journal of Biological Chemistry</i> , 2014 , 289, 23353-66	5.4	37
151	DPP-4 inhibitors: pharmacological differences and their clinical implications. 2014 , 13 Suppl 1, S57-68		562
150	Grape-seed procyanidins modulate cellular membrane potential and nutrient-induced GLP-1 secretion in STC-1 cells. <i>American Journal of Physiology - Cell Physiology</i> , 2014 , 306, C485-92	5.4	24
149	Cross-talk between SIRT1 and endocrine factors: effects on energy homeostasis. 2014 , 397, 42-50		15
148	Incretin attenuates diabetes-induced damage in rat cardiac tissue. 2014 , 64, 357-64		7
147	Prediction of remission after metabolic surgery using a novel scoring system in type 2 diabetes - a retrospective cohort study. 2014 , 13, 89		33
146	Denatonium induces secretion of glucagon-like peptide-1 through activation of bitter taste receptor pathways. 2014 , 57, 2117-25		72
145	Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor. 2014 , 3, 297-304		
144	Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. 2014 , 1842, 1693-706		230
143	Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. 2014 , 16, 812-8		42
142	RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice. 2014 , 307, G330-7		15
141	Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?. 2014 , 118, 1-18		143
140	Mechanism of the beneficial and protective effects of exenatide in diabetic rats. 2014 , 220, 291-304		30

139	Retraction Note: therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment. 2015 , 15, 34		2
138	A rare case of focal nesidioblastosis causing adult-onset hypoglycemia. 2015 , 10, 723-726		1
137	Emerging utility of once-weekly exenatide in patients with type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015 , 8, 505-12	3-4	3
136	A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. 2015 , 4, 212283		198
135	DPP4 in Diabetes. 2015 , 6, 386		216
134	The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?. 2015 , 2015, 806979		38
133	Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. 2015 , 47, e149		167
132	Assessment of ECell Function. 2015 , 45-69		
131	Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 242-9	14.6	11
130	DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY. 2015 , 53, 195-206		18
129	Efficacy of switching from premix analog insulin twice daily injection to insulin glargine once daily injection with sitagliptin. <i>Diabetology International</i> , 2015 , 6, 33-38	2.3	3
128	Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents. 2015 , 354, 279-89		47
127	Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis. 2015 , 9, 1528-1536		9
126	Making methods rugged for regulated bioanalysis. 2015 , 7, 833-52		4
125	The role of type 2 diabetes in neurodegeneration. 2015 , 84, 22-38		163
124	Swimming training prevents metabolic imprinting induced by hypernutrition during lactation. 2015 , 10, e13-e20		1
123	Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment. 2015 , 14, 15		11
122	Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. 2015 , 127, 463-79		10

121	Ghrelin regulates GLP-1 production through mTOR signaling in L cells. 2015 , 416, 9-18	17
120	Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function. 2015 , 197, 170-9	14
119	A Bovine Fibrinogen-Enriched Fraction as a Source of Peptides with in Vitro Renin and Angiotensin-I-Converting Enzyme Inhibitory Activities. 2015 , 63, 8676-84	35
118	Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development. 2015 ,	1
117	Duodenal-jejunal bypass improves diabetes and liver steatosis via enhanced glucagon-like peptide-1 elicited by bile acids. 2015 , 30, 308-15	12
116	Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes. 2015 , 85, 439-46	15
115	Metformin Combinatorial Therapy for Type 2 Diabetes Mellitus. 2016 , 5,	0
114	Microflora Disturbance during Progression of Glucose Intolerance and Effect of Sitagliptin: An Animal Study. 2016 , 2016, 2093171	49
113	Antihyperglycemic and Antiobesity Effects of JAL2 on db/db Mice. 2016 , 2016, 6828514	3
112	Exenatide extended-release for injectable suspension, BYDUREON [®] 2mg Pen. 2016 , 31, 156-161	1
111	A new stable GIP-Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus. 2016 , 87, 102-13	22
110	Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs-A mechanistic revisit to understand their mode of action. 2016 , 113, 636-674	41
109	Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?. 2016 , 15, 95	39
108	Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. 2016 , 12, 1	
107	Interactions between kidney disease and diabetes: dangerous liaisons. 2016 , 8, 50	76
106	Hypertension in type 2 diabetes: impact of glucose-lowering medications. 2016 , 5, 137-143	
105	Berberine attenuates high glucose-induced fibrosis by activating the G protein-coupled bile acid receptor TGR5 and repressing the S1P2/MAPK signaling pathway in glomerular mesangial cells. 2016 , 346, 241-7	13
104	TGR5 activation suppressed S1P/S1P2 signaling and resisted high glucose-induced fibrosis in glomerular mesangial cells. 2016 , 111, 226-236	13

103	Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment. 2016 , 27, 54-8		21
102	Identification of bioactive peptides from a papain hydrolysate of bovine serum albumin and assessment of an antihypertensive effect in spontaneously hypertensive rats. 2016 , 81, 91-99		47
101	Dysautonomia, Type 2 diabetes and vasculitis. 2016 , 6, 70-76		1
100	Neurobehavioral effects of liraglutide and sitagliptin in experimental models. 2016 , 774, 64-70		23
99	An overview of new GLP-1 receptor agonists for type 2 diabetes. 2016 , 25, 145-58		37
98	Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells. 2016 , 37, 2647-53		12
97	Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ventrolateral medulla in neonatal wistar rats. 2017 , 344, 74-88		8
96	Short-term, high-fat overfeeding impairs glycaemic control but does not alter gut hormone responses to a mixed meal tolerance test in healthy, normal-weight individuals. 2017 , 117, 48-55		25
95	Endocrine system on chip for a diabetes treatment model. 2017 , 9, 015021		25
94	A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus. 2017 , 86, 212-221		6
93	GLP-1 analogue CJC-1131 prevents amyloid β protein-induced impairments of spatial memory and synaptic plasticity in rats. <i>Behavioural Brain Research</i> , 2017 , 326, 237-243	3-4	6
92	Lactobacillus rhamnosus NCD17 ameliorates type-2 diabetes by improving gut function, oxidative stress and inflammation in high-fat-diet fed and streptozotocintreated rats. 2017 , 8, 243-255		56
91	Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF- κ B Activation. 2017 , 158, 4218-4232		26
90	Coumarins as potential antidiabetic agents. 2017 , 69, 1253-1264		83
89	Pathogenesis of Type 2 Diabetes Mellitus. 2017 , 267-277		2
88	The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. 2017 , 7, 4351		20
87	Adipocytokines, Energy Balance, and Cancer. <i>Energy Balance and Cancer</i> , 2017 ,	0.2	1
86	Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study. <i>Journal of Diabetes Investigation</i> , 2017 , 8, 341-345	3.9	8

85	Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. 2017 , 207, 114-120		75
84	Glucose-lowering drugs. 2017 , 298-322		
83	Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. 2017 , 22, 15-26		26
82	Cross-Talk Between Bile Acids and Gastro-Intestinal and Thermogenic Hormones: Clues from Bariatric Surgery. 2017 , 16, s68-s82		10
81	Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?. 2018 , 136, 335-342		15
80	Efficacy and safety of the G protein-coupled receptor 119 agonist DS-8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo-controlled study. <i>Journal of Diabetes Investigation</i> , 2018 , 9, 1333-1341	3.9	9
79	Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy. <i>Diabetes Research and Clinical Practice</i> , 2018 , 140, 279-287	7.4	4
78	Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin. <i>Brain Research Bulletin</i> , 2018 , 139, 67-80	3.9	18
77	Comparative treatment between sitagliptin vs. metformin, alone or in combination, in patients with polycystic ovary syndrome. A clinical entity at high risk for developing diabetes mellitus and gestational diabetes: A pilot study. <i>Revista Médica Del Hospital General De México</i> , 2018 , 81, 15-26	0	1
76	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , 2018 , 78, 13-42	12.7	103
75	Evolution of Glucose-Lowering Drugs for Type 2 Diabetes. 2018 , 431-454		2
74	A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target. <i>Frontiers in Bioscience - Landmark</i> , 2018 , 23, 1754-1779	2.8	14
73	Citrus bioflavonoids dipeptidyl peptidase-4 inhibition compared with gliptin antidiabetic medications. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 503, 21-25	3.4	13
72	Effect of narrowband ultraviolet B therapy on serum levels of CD26/dipeptidyl-peptidase IV and truncated forms of substance P in psoriasis patients with pruritus. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2019 , 12, 597-604	2.9	2
71	. 2019 ,		0
70	Trace amine-associated receptor 1 (TAAR1) promotes anti-diabetic signaling in insulin-secreting cells. <i>Journal of Biological Chemistry</i> , 2019 , 294, 4401-4411	5.4	19
69	Of mice and men: incretin actions in the central nervous system. <i>Metabolism: Clinical and Experimental</i> , 2019 , 98, 121-135	12.7	1
68	The Link Between Diabetes, Glucose Control, and Alzheimer's Disease and Neurodegenerative Diseases. 2019 , 89-115		

67	Understanding the link between insulin resistance and Alzheimer's disease: Insights from animal models. <i>Experimental Neurology</i> , 2019 , 316, 1-11	5.7	16
66	What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands. <i>Pharmacology & Therapeutics</i> , 2019 , 198, 90-108	13.9	12
65	An unusual case of a generalised cutaneous drug reaction to liraglutide. <i>European Journal of Dermatology</i> , 2019 , 29, 675-677	0.8	3
64	Role of hypothalamus-pituitary-adrenal axis modulation in the stress-resilient phenotype of DPP4-deficient rats. <i>Behavioural Brain Research</i> , 2019 , 356, 243-249	3.4	6
63	Multivalent activation of GLP-1 and sulfonylurea receptors modulates β cell second-messenger signaling and insulin secretion. <i>American Journal of Physiology - Cell Physiology</i> , 2019 , 316, C48-C56	5.4	4
62	All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes. <i>BMC Endocrine Disorders</i> , 2019 , 19, 3	3.3	3
61	Dipeptidyl peptidase-4 and adenosine deaminase enzyme levels in polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2019 , 35, 138-141	2.4	6
60	Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes. <i>Annals of Pharmacotherapy</i> , 2019 , 53, 371-384	2.9	3
59	Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 905-927	8.3	14
58	Combination use of liraglutide and insulin to Japanese patients with multiple insulin injection: efficacy and cost. <i>Diabetology International</i> , 2020 , 11, 49-56	2.3	
57	Baseline Characteristics of Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study. <i>Diabetes Therapy</i> , 2020 , 11, 1563-1578	3.6	3
56	Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression. <i>Journal of Diabetes Investigation</i> , 2020 , 11, 1137-1149	3.9	4
55	Deficiency of TGR5 exacerbates immune-mediated cholestatic hepatic injury by stabilizing the β catenin destruction complex. <i>International Immunology</i> , 2020 , 32, 321-334	4.9	8
54	Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection. <i>Heart Failure Reviews</i> , 2021 , 26, 437-450	3.5	4
53	Safety and pharmacokinetic interaction between fotaliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 725-731	5.5	
52	Dipeptidyl peptidase-IV inhibitory peptides derived from salmon milt and their effects on postprandial blood glucose level. <i>Fisheries Science</i> , 2021 , 87, 619-626	1.9	3
51	DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity. <i>Life Sciences</i> , 2021 , 278, 119574	6.8	2
50	A molecular link between diabetes and breast cancer: Therapeutic potential of repurposing incretin-based therapies for breast cancer. <i>Current Cancer Drug Targets</i> , 2021 ,	2.8	2

49	The Relevance of Off-Target Polypharmacology. 7-14		1
48	Peptide substrates of dipeptidyl peptidases. <i>Advances in Experimental Medicine and Biology</i> , 2006 , 575, 3-18	3.6	22
47	Type 2 Diabetes Mellitus: Epidemiology, Genetics, Pathogenesis, and Clinical Manifestations. 2010 , 203-220		1
46	Oral Agents for Type-2 Diabetes. 2011 , 93-122		1
45	The Gut and Type 2 Diabetes Mellitus. 2020 , 375-393		1
44	Pathogenesis of Type 2 Diabetes Mellitus. 2017 , 1-11		2
43	Gastrointestinal Hormones and Neurotransmitters. 2010 , 3-19.e4		4
42	Carbohydrates. 2011 , 210-225		7
41	Importance of postprandial glucose levels as a target for glycemic control in type 2 diabetes. <i>Southern Medical Journal</i> , 2009 , 102, 60-6	0.6	21
40	Pathophysiology and Clinical Management of Diabetes and Prediabetes. <i>Nutrition and Disease Prevention</i> , 2006 , 15-44		1
39	Managing Type 2 Diabetes Mellitus through Periodical Hospital Visits in the Aftermath of the Great East Japan Earthquake Disaster: A Retrospective Case Series. <i>PLoS ONE</i> , 2015 , 10, e0125632	3.7	14
38	Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus. <i>Journal of Clinical Medicine Research</i> , 2014 , 6, 327-35	2.9	23
37	Renal Function During an Open-Label Prospective Observational Trial of Sitagliptin in Patients With Diabetes: A Sub-Analysis of the JAMP Study. <i>Journal of Clinical Medicine Research</i> , 2018 , 10, 32-40	2.9	1
36	Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2009 , 2, 135-44	3.4	2
35	Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2006 , 2, 69-77	4.4	23
34	Lead Optimization Resources in Drug Discovery for Diabetes. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2019 , 19, 754-774	2.2	3
33	GLP-1(28-36)amide, a Long Ignored Peptide Revisited. <i>The Open Biochemistry Journal</i> , 2014 , 8, 107-11	0.9	6
32	No change in serum incretins levels but rise of leptin levels after smoking cessation: a pilot study. <i>Physiological Research</i> , 2016 , 65, 651-659	2.1	6

31	Effects of 7-Hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one from <i>Swietenia macrophylla</i> King Seed on Oxidized LDL, HOMA Beta and Glucagon like Peptide 1 (GLP-1) Gene Expression in Type 2 Diabetic Rats. <i>Asian Journal of Biochemistry</i> , 2017 , 12, 85-90	0.1	2
30	Elevated glucagon-like peptide-1 on a high-fat diet feeding prevents the incidence of diabetes mellitus in Spontaneously Diabetic Torii & Lepr rats. <i>Journal of Diabetes Mellitus</i> , 2012 , 02, 170-178	0.5	2
29	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of E3024, a Novel and Selective Dipeptidyl Peptidase-IV Inhibitor, in Healthy Japanese Male Subjects: Rash Development in Men and Its Possible Mechanism. <i>Pharmacology & Pharmacy</i> , 2013 , 04, 663-678	0.3	2
28	Glucagon Family of Peptides and their Receptors. 2004 , 193-196		
27	Nutrition Support and Hyperglycemia. <i>Nutrition and Disease Prevention</i> , 2006 , 171-192		
26	Ispol'zovanie inkretinov v lecheniisakharnogo diabeta 2 tipa - vcherashnyaya mechta, blizkaya k real'nosti segodnya. <i>Diabetes Mellitus</i> , 2006 , 9, 34-39	1.6	1
25	Diabetes in the Bariatric Surgery Patient. 2007 , 449-459		
24	The Effects of Exendin-4 on IRS-2 Expression and Phosphorylation in INS-1 Cells. <i>Korean Diabetes Journal</i> , 2008 , 32, 102		
23	Polypills for Treatment of Type 2 Diabetes. 2008 , 317-330		
22	Treatment Patterns in Youth with Diabetes. 2008 , 303-322		
21	Facile synthesis of glucagon-like peptide-1 (GLP-1) mimetics. <i>Advances in Experimental Medicine and Biology</i> , 2009 , 611, 119-20	3.6	
20	Rational design of peptidomimetics for class B GPCRs: potent non-peptide GLP-1 receptor agonists. <i>Advances in Experimental Medicine and Biology</i> , 2009 , 611, 125-6	3.6	1
19	INSULINS AND OTHER HYPOGLYCEMIC DRUGS. 2009 , 357-473		
18	Glucagon and the Glucagon-Like Peptides. 2010 , 660-672		
17	Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , 3, 363-72	3.4	2
16	The Effect of Adding Sitagliptin on Improving Glycemic Control in Combination with Multiple Antidiabetic Agents. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2012 , 38, 251-257	0.1	
15	Clinical Approaches to Preserving β Cell Function in Diabetes. 2014 , 1-24		
14	Clinical Approaches to Preserving β Cell Function in Diabetes. 2015 , 895-921		

13	Glucagon-like peptide. 2016 , 555		
12	Pathogenesis of Type 2 Diabetes Mellitus. 2016 , 1-11		
11	GI Peptides, Energy Balance, and Cancer. <i>Energy Balance and Cancer</i> , 2017 , 253-288	0.2	
10	Socio-medical aspects of the normalization of body mass. <i>Obesity and Metabolism</i> , 2016 , 13, 49-52	0.6	3
9	Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine Research</i> , 2019 , 11, 651-663	2.9	2
8	The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future. <i>Diabetes Mellitus</i> , 2019 , 22, 461-466	1.6	
7	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , 3, 215-26	3.4	5
6	Enhanced Incretin Effects of Exendin-4 Expressing Chimeric Plasmid Based On Two-Step Transcription Amplification System with Dendritic Bio-reducible Polymer for the Treatment of Type 2 Diabetes. 2013 , 1, 7-15		1
5	Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment.. <i>World Journal of Diabetes</i> , 2022 , 13, 85-96	4.7	0
4	In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update.. <i>Molecules</i> , 2021 , 27,	4.8	1
3	Bioactive peptides: Improving the future of diabetes therapy. 2022 , 41-74		0
2	Impact of Lycium barbarum polysaccharide on the expression of glucagon-like peptide 1 in vitro and in vivo. 2022 ,		0
1	Exacerbation mechanism of type 2 diabetes mellitus by periodontopathic bacterial dipeptidyl-peptidases (DPPs). 2023 , 65, 1-8		0